We used MK-2206, an allosteric AKT inhibitor presently being investigated in clinical trials, and tested its effect on migration, invasion and metastasis in NSCLC cell lines with and without KRAS or EGFR mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.